TechnologyPatent OppositionCompetitive Analysis

In the competitive field of Medicinal Compounds For Specific Treatments, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Medicinal Compounds For Specific Treatments technology and learn how to protect your intellectual property.

Get Patent Opposition Report for Medicinal Compounds For Specific Treatments

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Industry Landscape Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Medicinal Compounds For Specific Treatments industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Medicinal Compounds For Specific Treatments industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 31, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Medicinal Compounds For Specific Treatments industry

New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025ALFRED E TIEFENBACHER
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 22, 2025TEVA PHARMACEUTICALS
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 21, 2025CAMULON
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 18, 2025EGIS
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 16, 2025DR SCHON
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 14, 2025SYNTHON
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 1, 2025GENERICS UK
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJun 25, 2025ZENTIVA KS
Composition Comprising Micellar Whey Protein, Vitamin D And Clacium To Improve Or Maintain MuscleSOCIT DES PRODUITS NESTLJun 24, 2025FRESENIUS KABI DEUTSCHLAND
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSJun 23, 2025AMGEN

To stay ahead in the competitive Medicinal Compounds For Specific Treatments industry, companies are constantly innovating. Here are the top patents facing oppositions in the Medicinal Compounds For Specific Treatments industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS23
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY22
Nov 6, 2024Dosing Regimen Associated With Long Acting Injectable Paliperidone EstersJANSSEN PHARMACEUTICA20
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Oct 23, 2024New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS17
Oct 11, 2023New UseNOVARTIS16
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
Mar 8, 2023Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
Nov 13, 2019Apixaban FormulationsBRISTOL MYERS SQUIBB IRELAND12